DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

Information source: Hospital Governador Celso Ramos
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Blind Painful Eye; Refractory Glaucoma; Control of Pain Through Drug Injection

Intervention: Triamcinolone (Drug); Chlorpromazine (Drug)

Phase: N/A

Status: Completed

Sponsored by: Hospital Governador Celso Ramos

Official(s) and/or principal investigator(s):
Deborah C Ribas, MD, Principal Investigator, Affiliation: Hospital Governador Celso Ramos

Summary

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.

Clinical Details

Official title: Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Primary outcome: Changes in Pain intensity

Secondary outcome:

Changes in Use of eyedrops before and after drug injection

Changes in Intraocular pressure (IOP)

Detailed description: The management of chronic eye pain is a constant challenge to ophthalmology. Treatment varies with the intensity of pain, and topical eye drops and contact lens therapy are effective in many patients. In refractory cases, and without vision, surgical removal of the eye through enucleation is considered classical therapy. As less invasive alternatives we have cyclodestruction and neurolytic drug injection in order to promote analgesia for a prolonged period. The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of This is a prospective study of patients with blind painful eyes not responsive to topical treatment and with no indication for evisceration seen at the Department of Ophthalmology, Hospital Governador Celso Ramos (HGCR) in 2010.

Eligibility

Minimum age: 15 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- patients treated in the period at HGCR who wanted to be part of the protocol by

signing the consent form Exclusion Criteria:

- patients whose follow-up period was less than three months

Locations and Contacts

Hospital Governador Celso Ramos, Florianopolis, Santa Catarina 88015270, Brazil
Additional Information

Starting date: January 2010
Last updated: July 27, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017